Endo Health Solutions Inc. Pays $193 Million To Settle Labeling Violations
Endo Health Solutions agreed Friday to plead guilty and pay $192.7 million in a criminal and civil settlement related to its promotion of its pain medicine Lidoderm for uses not approved by the Food and Drug Administration. Under the terms of the plea agreement, Endo will pay $171.9 million to resolve claims of “off-label marketing” and a criminal fine of $20.8 million. Pennsylvania share's of settlement is $1.6 million.
Help employers find you! Check out all the jobs and post your resume.